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Abstract
Background: Epidemiological studies propose that obesity increases the risk of several cancers, including
melanoma. Obesity increases the expression of leptin, a multifunctional peptide produced predominantly by
adipocytes which may promote tumor growth. Several recently experiments have suggested that the tumors
growth is in need of endothelial progenitor cell (EPC) dependent generation of new blood vessels.
Our objectives in the present study were to examine the effects of leptin on melanoma growth, circulating EPCs
number and plasma levels of nitric oxide metabolites (NOx).
Methods: 2×1 0
6 B16F10 melanoma cells were injected to thirty two C57BL6 mice subcutaneously. The mice
were randomly divided into 4 groups (n = 8) in 8th day. Two groups were received twice daily intraperitoneal(i.p)
injections of either PBS or recombinant murine leptin (1 μg/g initial body weight). Two groups were received i.p.
injections of either 9F8 an anti leptin receptor antibody or the control mouse IgG at 50 μg/mouse every 3
consecutive days. By the end of the second week the animals were euthanized and blood samples and tumors
were analyzed.
Results: The tumor weight, EPC numbers and NOx level in leptin, PBS, 9F8, and IgG group were (3.2 ± 0.6, 1.7 ±
0.3, 1.61 ± 0.2,1.7 ± 0.3 g), (222.66 ± 36.5, 133.33 ± 171, 23.33 ± 18, 132.66 ± 27.26/ml of blood), and (22.47 ± 5.5,
12.30 ± 1.5, 6.26 ± 0.84, 15.75 ± 6.3 μmol/L) respectively. Tumors weight and size, circulating EPC numbers and
plasma levels of NOx were significantly more in the leptin than 9f8 and both control groups (p < 0.05). The plasma
concentration of NOx significantly decreased in 9f8 treated mice compare to control group (p < 0.05).
Conclusions: In conclusion, our observations indicate that leptin causes melanoma growth likely through
increased NO production and circulating EPC numbers and consequently vasculogenesis.
Introduction
Tumor growth and metastasis is dependent on the for-
mation and assembly of new blood vessels [1]. Several
recent experiments have suggested that the growth of
some types of tumors is not only dependent on angio-
genesis (i.e., mature endothelial-cell dependent genera-
tion of new blood vessels) but also is associated with
vasculogenesis, which means endothelial progenitor cell
(EPC) dependent generation of new blood vessels [2].
Mobilization of EPCs from the bone marrow constitu-
tes a critical step in the formation of de novo blood ves-
sels, and levels of peripheral blood EPCs have been
shown to be increased in certain malignant states.
Furthermore, inhibition of EPCrecruitment in neoplas-
tic conditions has been efficiently attenuated tumors
growth and progression [3-6]. In this regard, EPCs holds
potential pathophysiological role in melanoma and may
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and progression.
Leptin, a product of the obese (ob) gene, is a multi-
functional peptide produced predominantly by adipo-
cytes[7]. Besides itsseveral pleiotropic effects including
regulation of food intake and energy expenditure, repro-
ductionand immunefunctions, leptin has been found to
exerts angiogenic effects in vitro and in vivo, which are
mediated by enhancement of the endothelium derived
nitric oxide (NO) production[8,9], the expression of
vascular endothelial growth factor (VEGF) and VEGF-
receptor 2 and activation of endogenous fibroblastic-
growth factor -2 [10,11].
The leptin receptor (ObR) is expressed on various cell
types, including endothelial cells,[12,13] CD34-positive
hematopoietic cells,[14] and peripheral blood-derived
early and lateoutgrowth endothelial progenitor cells
[15,16]. Furthermore leptin increased the adhesion,
transmigration, and incorporation of early outgrowth
progenitor cells into experimental arterial lesions [15].
Nitric oxide (NO) is recognized as an important final
target of leptin effecton the endothelium. Leptin can
induce NO formation by directly activating endothelial
NO synthase through the Akt pathway[17,18].
Leptin receptors are expressed in mouse melanoma
cells, but there is very little previous information on the
relationship between leptin and melanoma. One epide-
miological study reported that high serum leptin was
positively correlated with melanoma risk [19]. Moreover,
it has been shown that leptin directly accelerated mela-
noma tumor growth in mice [20].
In the present study, we hypothesized that the leptin
may increase the EPC numbers and NO production in
peripheral blood of melanoma tumor bearing mice.
Methods
Cell culture
B16-F10 melanoma cells which can grow in the C57BL/
6 strain mouse were purchased from the National Cell
bank of Iran (NCBI, Pasteur institute of Iran). Cells
were cultured in DMEM supplemented with 4 mM L-
glutamine, 4.5 g/l glucose, 10% FBS, and antibiotics (100
μg/ml streptomycin, 100 μg/ml penicillin) under humi-
dified air with 5% CO2 at 37°C.
After 80% confluency of the melanoma cell monolayer
in culture, the cells were washed and detached with PBS
containing 0.25% trypsin and 0.03% EDTA and then pel-
leted by brief centrifugation at 100 g.T h es u p e r n a t a n t
was removed, cell pellets were resuspended in PBS, and
the cell number was counted.
Animal experiments
Six to 8 week-old male C57BL/6 mice were purchased
from Pasteur institute of Iran and served as recipient
mice for tumor inoculation. Mice were permitted
1 week to acclimate to the environment before experi-
ment. All mice were treated according to the guidelines
of the Institutional Ethics Committee.
C57BL/6 mice were inoculated with 2 × 10
6 B16-F10
melanoma cells subcutaneously in the right flank using
a disposable tuberculin syringe. The day of inoculation
was defined as day 0. Primary palpable tumors devel-
oped on day 6-7. On day 8, the tumor bearing mice
were randomly assigned into 4 groups and each group
contained 8 mice. Two groups received twice daily
intraperitoneal (i.p) injections of either PBS or recombi-
nant murine leptin (1 μg/g initial body weight). Two
groups received i.p. injections of either 9F8 monoclonal
antibody or the control mouse IgG at 50 μg/injection
every 3 consecutive days on days 8, 11 after tumor
induction. 9F8 is a monoclonal antibody to the human
leptin receptor (ObR) which has been developed by
Fazeli and Zarkesh-Esfahani and tested for antagonist
activity using a leptin signaling bioassay [21]. 9F8 anti-
body was a kind gift from Professor Richard Ross, Shef-
field University, UK. The mouse IgG was kindly gifted
by Dr Ali Mostafaei (Medical Biology Research Center,
Kermanshah University of Medical Sciences) At the day
14, all animals were euthanized via pentobarbital over-
dose. Tumors were then carefully dissected, and
weighed. Moreover, tumor volumes were calculated as
prolate spheroid: V = (4/3*π*(a)2*(b), were “a” is half of
the minor axis and “b” is half of the major axis of the
prolate spheroid. The weight of the mice was measured
immediately after tumor resection.
Flow cytometry quantification of EPC
Mice were bled through heart puncture for EPC enu-
meration by flowcytometry. EPC were quantified using
the endothelial murine markers VEGF receptor2(PE;
R&D Systems,), and CD34(FITC;eBioscience Inc., San-
Diego, California)and the CD45 (PerCP;Santa Cruz Bio-
technology, Inc., Santa Cruz, California)as described
previously with minor changes [22]. Briefly, blood col-
lected in EDTA containing tubes were incubated for
10 minutes with FcR-blocking (miltenyibiotec, Germany).
500 μl of whole blood was incubated with 4 μlo fC D 4 5 ,
8 μlo fK D R ,a n d5μl of CD34. Respective isotype con-
trols were used as anegativecontrol(eBioscience Inc., San-
Diego, California) at 5 μg/ml concentration each. The
samples were lysed before flow cytometry analysis.
After RBC lysis, cellsuspensions were evaluated
by a FACSCalibur (BD Biosciences). The numberof
CD45
dimCD34
+KDR
+ EPCswas determined by a two-
dimensional side-scatter fluorescencedot-plot analysis of
the sample after gating onthe lymphocyte population
(Figure 1). The number of EPCs was expressed per
1 mlblood [22].
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Mice were fasted for 14 h prior to sacrificing in order to
obtain fasted blood samples.
Plasma was isolated from whole blood collected and
total nitrite (NOx) was measured (R&D Systems) as an
indicator of endothelial release of NO as previously
described [23].
Moreover, plasma leptin concentration was measured
by ELISA kit (R&D Systems) in mice according to man-
ufacturer’s instructions.
Statistical analysis
Data are expressed as mean ± SD and were tested for
normal distribution with the Kolmogorov-Smirnov test.
Comparisons between groups were analysed by ANOVA
followed by the Bonferroni method as post hoc-test. Dif-
ferences in the weight of the mice were analyzed using
the paired-sample t test. Statistical significance was
assumed, if a null hypothesis could be rejected at p ≤
0.05. All statistical analysis was performed with SPSS 16
(SPSS Inc.).
Results
The plasma levels of leptin were significantly higher in
leptin group compared to all other groups of mice while
there was no significant difference between other groups
(Figure 2).
Body weights for each group of mice are shown in
Table 1. There was a significant weight loss in mice of
leptin group while the weight of the animals of 9F8
group increased significantly during the study. By the
end of the experiment there was a significant difference
between leptin and 9f8 group in body weight and also
between each group and its relevant control group.
The melanoma tumor weight of leptin treated mice
were significantly more than tumors from other groups
of mice while there was no significant difference
between other groups (Figure 3).
Leptin treatment also resulted in significant more circu-
lating EPCs in tumor bearing mice whereas there was no
significant difference between other groups (Figure 4).
The plasma concentration of NOx significantly
increased in leptin group and significantly decreased in
9f8 treated mice compare to respective control groups
(Figure 5).
Discussion
Adipose tissue secretes several adipokines that are sup-
posed to stimulate inflammation, cell proliferation and
angiogenesis. One of the most important member of
such adipokines family is leptin, which increases cell pro-
liferation in several tumor cell lines, enhances endothelial
cell migration in vitro, and has been suggested to be an
angiogenic/vasculogenic factor [12-17,20].
It has been suggested that leptin may contribute to
tumor growth. However, a direct cause and effect role
of leptin in accelerating tumor growth is uncertain.
Besides, most of the data supporting leptin’sr o l ei ns t i -
mulating cell proliferation and angiogenesis have been
derived from invitro studies.
In our study, the tumors weight of leptin treated mice
were significantly more than tumors from all other
groups of mice. Leptin has been identified in several
types of human cancers and may also be linked to poor
prognosis. In two studies, leptin and leptin receptor
expression were significantly increased in primary and
metastatic breast cancer relative to noncancerous tissues
in women [24]. In a clinical study of colorectal cancer,
leptin expression was associated with tumor G2 grade
[25]. In renal cell carcinomas leptin and leptin receptor
expression was well correlated with progression-free
a
b
c 
Figure 1 Characterization of endothelial progenitor cells (EPCs)
by flowcytometry evaluation. First, cells were plotted in forward
vs side scatter to gate the lymphocyte population selectively, where
EPCs are usually found (a). For analysis of CD45dimCD34+KDR+
endothelial progenitor cells, CD45 was then plotted against the side
scatter (b), followed by further analysis of the CD45dim population
on coexpression of CD34/KDR (c).
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[26]. Leptin has also been suggested to have a role in
uterine and endometrial cancers [27]. There is very little
previous information on the relationship between leptin
and melanoma. Just one epidemiological study demon-
strated that high serum leptin was positively correlated
with melanoma risk [19].
The limited published animal studies trying to find
whether leptin promote tumor growth have reported
different results. Some studies support the hypothesis
that the absence of leptin signaling diminishes mam-
mary tumor growth in mice [10,20,28,29].
Brandon et al, in their well-designed study have shown
that leptin deficiency attenuates but does not abolish
melanoma tumor growth [20].
Furthermore, In mouse model of mammary tumor,
using a leptin receptor antagonist [28]revealed that leptin
signaling promotes the growth of some types of mam-
mary tumors and increases the expression of proliferating
cell nuclear antigen, cyclin D1, vascular endothelial
growth factor (VEGF) and its receptor type two (VEGF-
R2) [30,31]. Furthermore Fusco et al have recently shown
that inactivation of LepR inhibits proliferation and viabi-
lity of human breast cancer cell lines [32]. Inconsistent
with the results of these studies, obese Zucker rats, which
have defective leptin receptor, developed more mammary
tumors than lean Zucker rats after exposure to the carci-
nogen, 7,12-dimethylbenzanthracene [33].
Leptin administration led to increase plasma NO con-
centrations as have been reported previously in several
other studies [34-37]. It has been shown that the leptin-
induced NO production is mediated through protein
kinase A and mitogen-activated protein kinase (MAPK)
activation. Interestingly antagonism of leptin by 9f8 anti-
body resulted in significantly lower plasma NO concen-
trations compare to both leptin and control group. The
significant effect of this antibody on NO production
despite of non-significant effects on tumor growth and
EPC numbers may be because of use of large, pharma-
cological concentrations of leptin to demonstrate the
2 latter effects in this study.
Leptin receptors are expressed in mouse melanoma
cells as well as EPCs [38].
The results of the present study indicated that leptin
enhance the numbers of EPCs in peripheral blood. Recent
* *
Figure 2 The plasma levels of leptin were significantly higher
in leptin group compared to all other groups of mice while
there was no significant difference between other groups.
* (p < 0.05).
Table 1 The weight of mice in each group of the study
group Mice weight1 Mice weight2 P(before-after)
IgG 23.41 ± 0.31 23.24 ± 0.479 p > 0.05
9f8 22.74 ± 0.30 25.37 ± 0.77* P < 0.05
leptin 22.68 ± 0.99 19.25 ± 1.53*g P < 0.05
PBS 24.37 ± 1.22 24.60 ± 1.20 p > 0.05
*Significant difference with respective control group.
gSignificant difference with 9F8 group.
* *
* *
Figure 3 Mean tumors size and weight. The weights and volume
of melanoma tumors excised from leptin treated mice were
significantly larger than tumors from other groups of mice. There
was no significant difference between three other study groups.
* (p < 0.05).
Figure 4 The circulating EPC numbers. Leptin treated melanoma
tumor bearing mice have more EPCs in peripheral blood than all
other study groups. There was no significant difference between
three other study groups. * (p < 0.05).
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also contributes to tumor vasculogenesis [3-5,39]. How-
ever the extent of EPCs incorporation into the tumor vas-
culature has been a subject of controversy [40-42]. To the
best of our knowledge, this is the first time that has been
shown that leptin increased EPCs in melanoma tumor
model. It has been recently reported that leptin increased
the adhesion and the homing potential of EPCs and may
thus enhance their capacity to promote vascular regenera-
tion in vivo [38]. Leptin induces NO, an important media-
tor of EPC mobilization. NO may trigger EPC recruitment
from bone marrow probably by activating a phosphatidyli-
nositol (PI) 3-kinase-independentAkt-eNOS phosphoryla-
tion pathway [42,43]. So, the mechanism of increased
EPCs in the circulation may be due to mobilization of
these cells from bone marrow. Furthermore it has been
shown that leptin can increase other mediators of vasculo-
genesis such as VEGF, and intracellular signaling pathways
of cell proliferation, including p38 MAPK and ERK1/2
MAPK phosphorylation [44].
Conclusion
In conclusion, our observations indicate that leptin
causes melanoma growth. The mechanisms by which
leptin promotes melanoma growth likely involve
increased NO production and circulating EPC numbers
and consequently vasculogenesis.
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